![](https://endpts.com/wp-content/uploads/2020/09/Maureen-Hillenmeyer-Hexagon-Bio-tile-scaled.jpg)
Maureen Hillenmeyer, Hexagon Bio CEO
Using AI to sequence fungi genomes for cancer treatments, Hexagon Bio nets $47M in Series A
A Stanford spinout exploring how fungi can be sequenced to discover new medicines in oncology and infectious diseases now has significantly more cash to do …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.